Foreign brands ask me all the time how to get into Chinese hospitals and pharmacies. Almost none of them ask who is actually going to move their product from the port to the shelf, get paid for it, and not disappear with the stock. That second question matters more. Distribution is where most pharma launches in China quietly die, months after the market-access plan looked solid on paper.
This is the distributor-side companion to Pharma in China: Where the Opportunities Are, which covers market access, tenders, and reimbursement from the brand’s point of view. That article tells you where to sell. This one tells you who you will be forced to sell through, and why that choice can make or break the whole plan.
I’m Olivier Verot, founder of GMA. I’ve been based in Shanghai since 2012 and watched a good number of pharma and health product launches stall not because the product was wrong, but because the distributor contract was signed too fast.
A handful of giants, thousands of everyone else
China’s pharmaceutical distribution market is one of the most concentrated at the top and one of the most fragmented everywhere else. Four national groups, known in the industry as the “4+N” structure, control the top of the pyramid: Sinopharm (国药), Shanghai Pharma (上药), China Resources Pharmaceutical (华润医药), and Jiuzhou Pharmaceutical (九州通). Together they held a combined market share, or CR4, of 41.32% in 2023, up from 37.71% the year before. Sinopharm alone sits at roughly 20.4%, according to industry data reported by Yaoyao Jingji Bao.
Below those four, the market falls apart into thousands of small, regional operators. China counted around 14,800 licensed wholesale distributors as of the most recent industry tally, most of them provincial or municipal players with a handful of hospital or pharmacy relationships each. That is not a footnote, it is the actual structure a foreign brand has to work within. You are not choosing between a few professional national players. You are choosing between a national giant who will treat your small brand as a rounding error, and a regional distributor who might genuinely care about your product but has none of the reach.
Every distributor operates under a GSP license (药品经营质量管理规范, Good Supply Practice), and the license defines exactly what that company is allowed to do: which product categories, which provinces, which type of client. A distributor licensed to sell to retail pharmacies in Jiangsu cannot legally ship into a Beijing hospital network without going through a separate delegation process. When a license holder wants a distributor to handle cross-provincial sales, both the license holder’s local regulator and the distributor’s local regulator have to be notified and sign off, under rules the National Medical Products Administration tightened in 2024. Brands read “national distribution agreement” on a contract and assume it means what it says. In practice, it often means the distributor has to route half the country through sub-agents you never meet and never vet.
The margin squeeze that now hits distributors too
Centralized volume-based procurement, 集采 (VBP), used to be a manufacturer’s problem. A drug gets selected into a national bulk-buying round, the price collapses in exchange for guaranteed volume, and the manufacturer absorbs the hit. That is no longer where the story ends. By February 2026, China had run eight national VBP rounds covering 316 drugs across 26 therapeutic areas, from anti-infectives to oncology to cardiovascular, with procurement contracts running through the end of 2028. Prices on VBP-listed drugs are public and fixed. There is no negotiating room left in the hospital channel for either the manufacturer or the distributor sitting between them.
What this means in practice: distributors who used to make their margin partly on price flexibility now make it almost entirely on service, logistics efficiency, and volume. A distributor with old-fashioned operations, manual reconciliation, slow warehouses, no cold-chain automation, is bleeding margin on every VBP-listed unit it moves. That is why the stronger regional players are pushing hard into supply-chain services and digital ordering, and why the weaker ones are the ones a foreign brand should be most wary of signing with. A distributor squeezed on margin looks for ways to make it up elsewhere, and “elsewhere” is not always something you want attached to your brand.
Getting paid is its own business problem
This is the part nobody explains to a foreign brand before they sign. 账期, the payment term a distributor waits to be paid by a hospital, is long in China. Not thirty days, not sixty. A 2024 survey of 630 wholesale enterprises across 31 provinces by the China Pharmaceutical Commerce Association found an average of 154 days between delivery to a hospital and payment, and that number has been drifting up, not down, over the last five years. Some listed distribution companies report far worse: several publicly traded firms carried receivable cycles above 230 days through 2025 and into 2026, and one, 合富中国, crossed 400 days in its first-quarter 2026 filing, according to reporting from Sina Finance.
Now put yourself in the distributor’s shoes. They pay the manufacturer, or you, close to on delivery or on short terms. They wait five, six, sometimes twelve months to collect from the hospital. That gap is financed out of their own working capital, or a bank line, or your goodwill. A small regional distributor with a thin balance sheet cannot carry that gap forever. When the gap gets too wide, one of three things happens: they slow-pay you, they stop reordering even if the product sells, or they quietly start prioritizing whichever brand pays them the fattest rebate to keep the relationship alive. None of that shows up in a due diligence deck. It shows up eight months in, when your reorder volume mysteriously drops and nobody tells you why.
There is a policy fix underway. The government has pushed hospitals toward instant settlement (即时结算) through the National Healthcare Security Administration, targeting 80% of eligible hospital transactions on instant terms by the end of 2026. It is real progress. It is also not evenly rolled out, and a distributor’s exposure today still depends heavily on which province and which hospital tier they sell into.
Counterfeit risk does not disappear with a signed contract
Every extra intermediary between your factory and the patient is another point where product can be swapped, diluted, relabeled, or simply lost and replaced with something cheaper. For some categories the chain still runs five or six layers deep: importer, national distributor, provincial sub-distributor, city-level agent, hospital procurement, pharmacy. A GSP license proves a company is legally allowed to handle drugs. It does not prove they track every batch through every hand it passes through. Ask a prospective distributor how they trace a batch number from your warehouse to the point of sale, and watch how long it takes them to answer. A confident, specific answer is a good sign. A vague one about “our internal system” is not.
The counterfeit risk is not evenly distributed either. It concentrates in the long tail, the thousands of small regional distributors competing for margin on VBP-squeezed products, exactly the same companies most likely to be financially stretched by hospital payment delays. The two risks I’ve described, margin pressure and payment delays, feed the third one. A distributor under cash pressure has more reason to cut a corner they would not have cut two years ago.
What this looked like for one brand
Ingrid runs a small Norwegian company selling a specialized over-the-counter respiratory product. She signed with a mid-sized regional distributor in 2024 who promised coverage across three provinces and a fast route into hospital pharmacies. For the first seven months, orders looked healthy. Then reorders slowed to almost nothing, without an explanation beyond vague messages about “market conditions.”
She tried renegotiating price, assuming the distributor wanted better margin. It changed nothing, because price was never the problem. When her team finally pulled the distributor’s payment history from the hospitals they supplied, the real issue surfaced: two of the three hospital networks were paying that distributor on 200-plus day terms, and the distributor had run out of working capital to keep restocking her product while waiting to collect. They weren’t rejecting her brand. They were financially unable to keep buying it.
The fix was not a better contract clause. It was splitting the distribution across two partners: the original regional distributor kept the two provinces where its hospital relationships were strong, and a second, better-capitalized distributor took over the province with the worst payment terms. Reorders recovered within four months, and her China revenue stabilized at roughly 30% above the pre-crisis run rate a year later, because the second distributor could actually carry the receivable gap the first one could not. The lesson was not about finding a “better” distributor. It was about matching each distributor’s financial capacity to the payment reality of the territory they were covering.
How to actually choose a distributor
Most foreign brands evaluate a Chinese pharma distributor the way they would evaluate one back home: coverage, references, price. That misses the three things that actually predict whether the relationship survives year two.
- Check the GSP license scope directly, not the sales pitch. Which provinces, which product categories, which client types is the distributor actually licensed for, and where do they need a delegation filing to operate.
- Ask for their receivable days on hospital business, not their revenue figures. A distributor proud of fast collection will tell you. One who dodges the question has a cash flow problem they are not ready to admit to a new partner.
- Get specific on batch traceability before you sign, not after a problem surfaces. Ask them to walk through, step by step, how a single batch is tracked from your warehouse to the final point of sale.
- Match distributor size to territory reality. A brand with a modest product line does not need Sinopharm-scale hospital reach, and forcing that fit usually means being ignored. It needs a distributor whose balance sheet can absorb the payment delay of the specific hospitals it covers.
None of this is unique to pharma. We wrote about the same trust problem, from a different angle, when covering what happens when a distributor starts competing against the brand it represents. The pattern repeats across categories: the contract is never the real protection. The financial health and the incentives of the company standing between you and the patient are.
Foreign health and wellness brands face a related version of this problem outside pure pharma, covered in our guide to partnering with supplement and vitamin distributors in China, and in our broader healthcare market export guide. The regulatory details differ, the underlying distributor risk does not.
FAQ
Can I work with more than one distributor at once in China?
Yes, and for most brands beyond a single province it is the safer approach. Splitting territory between two or three distributors, matched to their financial capacity and hospital relationships, spreads both the payment-delay risk and the counterfeit risk instead of concentrating it in one company that may be financially stretched.
How do I know if a distributor is financially healthy enough to work with?
Ask directly for their average hospital receivable days and how they finance the gap between paying you and collecting from hospitals. A distributor unwilling to discuss this, or one whose answer is vague, is telling you something even if they don’t mean to. For listed distributors, receivable turnover days are public in their financial filings.
Who is Gentlemen Marketing Agency?
We are a Shanghai-based agency and we do not sell pharmaceutical distribution services ourselves. What we do is help foreign pharma and healthcare brands evaluate the digital and reputational side of a China entry: due diligence on how a distributor and its network actually show up online, hospital and pharmacy digital positioning, and the KOL and content work that supports a launch once the distribution question is settled. If you are weighing distributor options and want a second pair of eyes on the digital and reputational side, get in touch.
